Table 1 Characteristics of the study population
From: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis
Normal liver (NL) (n = 36) | Mild fibrosis (F0-F2) (n = 52) | Advanced fibrosis (F3-F4) (n = 33) | |
|---|---|---|---|
Age (years) | 56.82 ± 12.48 | 52.75 ± 11.89 | 60.64 ± 9.37## |
Gender (female/male, %) | 58.33 / 41.67 | 59.62 / 40.38 | 48.48 / 51.52 |
BMI (kg/m2) | 27.72 ± 5.93 | 34.92 ± 7.99**** | 32.6 ± 4.63*** |
Glucose (mg/dL) | 94.17 ± 12.76 | 125.9 ± 55.49** | 120 ± 46.13** |
Diabetes (%) | 11.1 | 53.8**** | 75.8****# |
Triglycerides (mg/dL) | 107.2 ± 53.23 | 181 ± 133.7**** | 159.7 ± 74.75*** |
Total cholesterol (mg/dL) | 186 ± 41.1 | 197.5 ± 46.83 | 194.4 ± 35.55 |
AST (IU/L) | 19.5 ± 5.79 | 61 ± 121.6**** | 48.15 ± 29.74**** |
ALT (IU/L) | 20.58 ± 12.03 | 67.33 ± 86.66**** | 54.97 ± 35.9**** |
GGT (IU/L) | 40.39 ± 29.79 | 96.52 ± 158** | 136.5 ± 189.1****# |
Platelets (109/L) | 233.3 ± 65.5 | 234.1 ± 64.38 | 186.6 ± 68.56**### |
Albumin (g/L) | 44.85 ± 3.61 | 45.3 ± 3.64 | 44.71 ± 3.16 |
Fibrosis (%) | |||
Stage 0 | 100% | 32.7% | |
Stage 1 | 40.38% | ||
Stage 2 | 26.92% | ||
Stage 3 | 66.67% | ||
Stage 4 | 33.33% | ||